Wuhan, China

Guohong Peng

This inventor holds 1 USPTO granted patent. Top assignee: Wuhan Miracle Laser Co., Ltd. Active years: 2013.


Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Guohong Peng: Innovator in Laser Therapeutic Technology

Introduction

Guohong Peng is a prominent inventor based in Wuhan, China. He is known for his contributions to the field of laser technology, particularly in therapeutic applications. His innovative work has led to the development of advanced laser devices that enhance medical treatments.

Latest Patents

Guohong Peng holds a patent for a multifunctional laser therapeutic apparatus. This apparatus includes a 532 nm wavelength laser or a 2000 nm wavelength thulium laser, a 980 nm wavelength laser or a 1470 nm wavelength laser, and a 2100 nm wavelength laser. The device features an optical coupling mechanism that integrates the emitted lasers into a single optical fiber for effective treatment. Additionally, it includes a control device that manages the operational modes and energy output of the lasers.

Career Highlights

Guohong Peng is associated with Wuhan Miracle Laser Co., Ltd., where he has made significant strides in laser technology. His work has not only advanced therapeutic applications but has also contributed to the overall growth of the medical laser industry.

Collaborations

Guohong has collaborated with notable colleagues such as Wen Sun and Zhangqun Ye. Their combined expertise has fostered innovation and development in laser therapeutic solutions.

Conclusion

Guohong Peng's contributions to laser technology exemplify the impact of innovation in medical treatments. His patented multifunctional laser therapeutic apparatus represents a significant advancement in the field, showcasing his dedication to improving healthcare through technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…